Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma.
LTB
NF‐κB
NIK
RelB
cholangiocarcinoma
small molecule inhibitor B022
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
revised:
25
07
2024
received:
21
03
2024
accepted:
02
08
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
21
8
2024
Statut:
aheadofprint
Résumé
Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the intrahepatic (iCCA) or extrahepatic (eCCA) bile ducts with poor prognosis and limited treatment options. Prior evidence highlighted a significant contribution of the non-canonical NF-κB signalling pathway in initiation and aggressiveness of different tumour types. Lymphotoxin-β (LTβ) stimulates the NF-κB-inducing kinase (NIK), resulting in the activation of the transcription factor RelB. However, the functional contribution of the non-canonical NF-κB signalling pathway via the LTβ/NIK/RelB axis in CCA carcinogenesis and progression has not been established. Human CCA-derived cell lines and organoids were examined to determine the expression of NF-κB pathway components upon activation or inhibition. Proliferation and cell death were analysed using real-time impedance measurement and flow cytometry. Immunoblot, qRT-PCR, RNA sequencing and in situ hybridization were employed to analyse gene and protein expression. Four in vivo models of iCCA were used to probe the activation and regulation of the non-canonical NF-κB pathway. Exposure to LTα1/β2 activates the LTβ/NIK/RelB axis and promotes proliferation in CCA. Inhibition of NIK with the small molecule inhibitor B022 efficiently suppresses RelB expression in patient-derived CCA organoids and nuclear co-translocation of RelB and p52 stimulated by LTα1/β2 in CCA cell lines. In murine CCA, RelB expression is significantly increased and LTβ is the predominant ligand of the non-canonical NF-κB signalling pathway. Our study confirms that the non-canonical NF-κB axis LTβ/NIK/RelB drives cholangiocarcinogenesis and represents a candidate therapeutic target.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the intrahepatic (iCCA) or extrahepatic (eCCA) bile ducts with poor prognosis and limited treatment options. Prior evidence highlighted a significant contribution of the non-canonical NF-κB signalling pathway in initiation and aggressiveness of different tumour types. Lymphotoxin-β (LTβ) stimulates the NF-κB-inducing kinase (NIK), resulting in the activation of the transcription factor RelB. However, the functional contribution of the non-canonical NF-κB signalling pathway via the LTβ/NIK/RelB axis in CCA carcinogenesis and progression has not been established.
METHODS
METHODS
Human CCA-derived cell lines and organoids were examined to determine the expression of NF-κB pathway components upon activation or inhibition. Proliferation and cell death were analysed using real-time impedance measurement and flow cytometry. Immunoblot, qRT-PCR, RNA sequencing and in situ hybridization were employed to analyse gene and protein expression. Four in vivo models of iCCA were used to probe the activation and regulation of the non-canonical NF-κB pathway.
RESULTS
RESULTS
Exposure to LTα1/β2 activates the LTβ/NIK/RelB axis and promotes proliferation in CCA. Inhibition of NIK with the small molecule inhibitor B022 efficiently suppresses RelB expression in patient-derived CCA organoids and nuclear co-translocation of RelB and p52 stimulated by LTα1/β2 in CCA cell lines. In murine CCA, RelB expression is significantly increased and LTβ is the predominant ligand of the non-canonical NF-κB signalling pathway.
CONCLUSIONS
CONCLUSIONS
Our study confirms that the non-canonical NF-κB axis LTβ/NIK/RelB drives cholangiocarcinogenesis and represents a candidate therapeutic target.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 469332207
Organisme : Deutsche Forschungsgemeinschaft
ID : 493697503
Organisme : Deutsche Forschungsgemeinschaft
ID : 469903177
Organisme : Deutsche Krebshilfe
ID : 70113922
Organisme : Deutsche Krebshilfe
ID : 70113593
Informations de copyright
© 2024 The Author(s). Liver International published by John Wiley & Sons Ltd.
Références
Sarcognato S, Sacchi D, Fassan M, et al. Cholangiocarcinoma. Pathologica. 2021;113(3):158‐169.
Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557‐588.
Hayden MS, Ghosh S. Shared principles in NF‐kappaB signaling. Cell. 2008;132(3):344‐362.
Sun SC. Non‐canonical NF‐kappaB signaling pathway. Cell Res. 2011;21(1):71‐85.
Sun SC. The non‐canonical NF‐κB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545‐558.
Ghosh S, Karin M. Missing pieces in the NF‐kappaB puzzle. Cell. 2002;109(2):S81‐S96.
Tumanov AV, Christiansen PA, Fu YX. The role of lymphotoxin receptor signaling in diseases. Curr Mol Med. 2007;7(6):567‐578.
Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin‐beta receptor induces different patterns of gene expression via two NF‐kappaB pathways. Immunity. 2002;17(4):525‐535.
Müller JR, Siebenlist U. Lymphotoxin beta receptor induces sequential activation of distinct NF‐kappa B factors via separate signaling pathways. J Biol Chem. 2003;278(14):12006‐12012.
Mulero MC, Huxford T, Ghosh G. NF‐κB, IκB, and IKK: integral components of immune system signaling. Adv Exp Med Biol. 2019;1172:207‐226.
Scherr AL, Nader L, Xu K, et al. Etiology‐independent activation of the LTbeta‐LTbetaR‐RELB axis drives aggressiveness and predicts poor prognosis in hepatocellular carcinoma. Hepatology. 2023;80(2):278‐294.
Luedde T, Schwabe RF. NF‐kappaB in the liver–linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108‐118.
Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF‐κB: a blossoming of relevance to human pathobiology. Cell. 2017;168(1–2):37‐57.
Elssner C, Goeppert B, Longerich T, et al. Nuclear translocation of RELB is increased in diseased human liver and promotes ductular reaction and biliary fibrosis in mice. Gastroenterology. 2019;156(4):1190‐1205.e14.
Affo S, Nair A, Brundu F, et al. Promotion of cholangiocarcinoma growth by diverse cancer‐associated fibroblast subpopulations. Cancer Cell. 2021;39(6):883.
Gürlevik E, Fleischmann‐Mundt B, Armbrecht N, et al. Adjuvant gemcitabine therapy improves survival in a locally induced, R0‐resectable model of metastatic intrahepatic cholangiocarcinoma. Hepatology. 2013;58(3):1031‐1041.
Yamada D, Ilyas SI, Razumilava N, et al. IL‐33 facilitates oncogene‐induced cholangiocarcinoma in mice by an interleukin‐6‐sensitive mechanism. Hepatology. 2015;61(5):1627‐1642.
Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122(8):2911‐2915.
Onori P, DeMorrow S, Gaudio E, et al. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF‐kappaB and induction of apoptosis. Int J Cancer. 2009;125(3):565‐576.
Seubwai W, Vaeteewoottacharn K, Hiyoshi M, et al. Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF‐kappaB. Cancer Sci. 2010;101(7):1590‐1595.
Seubwai W, Wongkham C, Puapairoj A, et al. Aberrant expression of NF‐κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy. PLoS ONE. 2014;9(8):e106056.
Shiode Y, Kodama T, Shigeno S, et al. TNF receptor‐related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase‐mediated hepatocyte transdifferentiation. Hepatology. 2023;77(2):395‐410.
Li X, Wu Y, Song Y, et al. Activation of NF‐κB‐inducing kinase in islet β cells causes β cell failure and diabetes. Mol Ther. 2020;28(11):2430‐2441.
Ren X, Li X, Jia L, et al. A small‐molecule inhibitor of NF‐κB‐inducing kinase (NIK) protects liver from toxin‐induced inflammation, oxidative stress, and injury. FASEB J. 2017;31(2):711‐718.
Li Z, Li X, Su MB, et al. Discovery of a potent and selective NF‐κB‐inducing kinase (NIK) inhibitor that has anti‐inflammatory effects in vitro and in vivo. J Med Chem. 2020;63(8):4388‐4407.
Li Y, Chen M, Zhou Y, et al. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease. Theranostics. 2020;10(8):3579‐3593.
Broutier L, Mastrogiovanni G, Verstegen MMA, et al. Human primary liver cancer‐derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424‐1435.
Tyson GL, El‐Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173‐184.
Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch‐mediated conversion of hepatocytes. J Clin Invest. 2012;122(11):3914‐3918.
Vicent S, Lieshout R, Saborowski A, et al. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver Int. 2019;39(suppl. 1):79‐97.
Scarzello AJ, Jiang Q, Back T, et al. LTβR signalling preferentially accelerates oncogenic AKT‐initiated liver tumours. Gut. 2016;65(10):1765‐1775.
Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin‐driven pathway to hepatocellular carcinoma. Cancer Cell. 2009;16(4):295‐308.
Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(suppl. 1):19‐31.
Nejak‐Bowen K. If it looks like a duct and acts like a duct: on the role of reprogrammed hepatocytes in cholangiopathies. Gene Expr. 2020;20(1):19‐23.
Tarlow BD, Pelz C, Naugler WE, et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell. 2014;15(5):605‐618.
Yanger K, Zong Y, Maggs LR, et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 2013;27(7):719‐724.
Wang J, Dong M, Xu Z, et al. Notch2 controls hepatocyte‐derived cholangiocarcinoma formation in mice. Oncogene. 2018;37(24):3229‐3242.
Koehler BC, Scherr AL, Lorenz S, et al. Beyond cell death—antiapoptotic Bcl‐2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS ONE. 2013;8(10):e76446.
Nuciforo S, Fofana I, Matter MS, et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 2018;24(5):1363‐1376.
Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11(5):1475‐1489.
Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458‐1461.
Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014;184(4):912‐923.
Seehawer M, Heinzmann F, D'Artista L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018;562(7725):69‐75.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biol. 2014;15(12):550.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284‐287.
Gu Z, Hübschmann D. simplifyEnrichment: a bioconductor package for clustering and visualizing functional enrichment results. Genom Proteom Bioinform. 2023;21(1):190‐202.
Badia IMP, Vélez Santiago J, Braunger J, et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform Adv. 2022;2(1):vbac016.
Schubert M, Klinger B, Klünemann M, et al. Perturbation‐response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018;9(1):20.
Rio DC, Ares M, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc. 2010;2010(6):pdb.prot5439.
Gdynia G, Sauer SW, Kopitz J, et al. The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. Nat Commun. 2016;7:10764.